Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk
Yu Tian,Andre E Kim,Stephanie A Bien,Yi Lin,Conghui Qu,Tabitha A Harrison,Robert Carreras-Torres,Virginia Díez-Obrero,Niki Dimou,David A Drew,Akihisa Hidaka,Jeroen R Huyghe,Kristina M Jordahl,John Morrison,Neil Murphy,Mireia Obón-Santacana,Cornelia M Ulrich,Jennifer Ose,Anita R Peoples,Edward A Ruiz-Narvaez,Anna Shcherbina,Mariana C Stern,Yu-Ru Su,Franzel J B van Duijnhoven,Volker Arndt,James W Baurley,Sonja I Berndt,D Timothy Bishop,Hermann Brenner,Daniel D Buchanan,Andrew T Chan,Jane C Figueiredo,Steven Gallinger,Stephen B Gruber,Sophia Harlid,Michael Hoffmeister,Mark A Jenkins,Amit D Joshi,Temitope O Keku,Susanna C Larsson,Loic Le Marchand,Li Li,Graham G Giles,Roger L Milne,Hongmei Nan,Rami Nassir,Shuji Ogino,Arif Budiarto,Elizabeth A Platz,John D Potter,Ross L Prentice,Gad Rennert,Lori C Sakoda,Robert E Schoen,Martha L Slattery,Stephen N Thibodeau,Bethany Van Guelpen,Kala Visvanathan,Emily White,Alicja Wolk,Michael O Woods,Anna H Wu,Peter T Campbell,Graham Casey,David V Conti,Marc J Gunter,Anshul Kundaje,Juan Pablo Lewinger,Victor Moreno,Polly A Newcomb,Bens Pardamean,Duncan C Thomas,Konstantinos K Tsilidis,Ulrike Peters,W James Gauderman,Li Hsu,Jenny Chang-Claude
DOI: https://doi.org/10.1093/jnci/djac094
2022-08-08
Abstract:Background: The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. Methods: We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2- or 3-degree-of-freedom joint test. A set-based score test was applied for rare genetic variants. Results: The use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2-degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P < 1.2 × 10-4). Conclusion: Genetic variants that modify the association between MHT and CRC risk were identified, offering new insights into pathways of CRC carcinogenesis and potential mechanisms involved.